| Literature DB >> 32695233 |
Ana María Castellano-Guerrero1, Raquel Guerrero2,3, Desireé Ruiz-Aranda4, Sofia Perea5, Alfonso Pumar2,3, Federico Relimpio2,3, Miguel Angel Mangas2,3, Fernando Losada2,3, Maria Asunción Martínez-Brocca1,3.
Abstract
BACKGROUND: To assess gender differences in Quality of life (QoL) and in sociodemographic, clinical and psychological factors associated with impaired QoL in adults with long-standing type 1 diabetes mellitus (DM1).Entities:
Keywords: Gender differences; Quality of life; Type 1 diabetes mellitus
Year: 2020 PMID: 32695233 PMCID: PMC7367231 DOI: 10.1186/s13098-020-00571-x
Source DB: PubMed Journal: Diabetol Metab Syndr ISSN: 1758-5996 Impact factor: 3.320
Sociodemographic and clinical data
| Total | Male | Female | |
|---|---|---|---|
| Number of patients (n, %) | 312, 100% | 161, 51.6% | 151, 48.4% |
| Age (years) | 38.2 ± 12.7 | 38.7 ± 12.7 | 37.7 ± 12.6 |
| Education (years) | 13.4 ± 4.7 | 13.2 ± 4.8 | 13.6 ± 4.7 |
| Marital status: | |||
| Single | 103 (33%) | 54 (33.5%) | 49 (32.4%) |
| Married | 151 (48.4%) | 75 (46.5%) | 76 (50.3%) |
| Divorced | 23 (7.3%) | 15 (9.4%) | 8 (5.4%) |
| Widowed | 6 (1.9%) | 2 (1.3%) | 4 (2.6%) |
| In a relationship | 29 (9.3%) | 15 (9.3%) | 14 (9.3%) |
| Age at diagnosis (years) | 17.7 ± 10.7 | 17.6 ± 11.1 | 17.7 ± 10.3 |
| Duration of diabetes (years) | 20.4 ± 12 | 20.7 ± 12.4 | 19.9 ± 11.6 |
| HbA1c (%) | 7.5 ± 1.1 | 7.5 ± 1.2 | 7.5 ± 1 |
| Glycemic Instabilitya | 9.2 ± 8.3 | 9.4 ± 9.3 | 8.4 ± 7.1 |
| Hypertension | 77 (24.6%) | 47 (29.2%) | 30 (19.9%)* |
| Unawareness hypoglycemic | 95 (30.4%) | 54 (33.5%) | 41 (27.1%) |
| Severe hypoglycemia (last year): | |||
| 0 | 244 (78.2%) | 127 (78.9%) | 117 (77.5%) |
| 1 | 35 (11.2%) | 18 (11.2%) | 17 (11.25%) |
| > 1 | 33 (10.6%) | 16 (9.9%) | 17 (11.25%) |
| Intensive insulin regimen: | 312 (100%) | 161 (100%) | 151 (100%) |
| Bolus Basal | 287 (92%) | 152 (94.4%) | 135 (89.4%) |
| CSII | 23 (7.4%) | 9 (5.6%) | 14 (9.3%) |
| Insulin regimen < 2 shots a day | 2 (0.6%) | 0 (0.0%) | 2 (1.3%) |
| Microvascular complications: | 192 (61.5%) | 108 (67%) | 84 (55.6%) |
| Retinopathy | 107 (34.3%) | 61 (37.9%) | 46 (30.5%) |
| Nephropathy | 62 (19.9%) | 34 (21.1%) | 28 (18.5%) |
| Neuropathy | 23 (7.4%) | 13 (8.1%) | 10 (6.6%) |
| Macrovascular complications | 14 (4.5%) | 11 (6.8%) | 3 (1.9%)* |
| Fear of hypoglycemia | 139 (44.6%) | 70 (43.5%) | 69 (45.7%) |
| Depression (MINI) | 72 (23.1%) | 24 (14.9%) | 48 (31.7%)* |
| Anxiety (MINI) | 56 (17.9%) | 21 (13%) | 35 (23.2%)* |
Data are expressed as Mean ± SD or n (%)
Prevalence of Fear of Hypoglycemia is calculated according to FH-15 questionnaire
CSII, Continuous subcutaneous insulin infusion; MINI, Planned psychological interview
aGlycemic instability is defined as number of episodes of severe hypoglycaemia, mild hypoglycaemia (≤ 70 mg/dl) and hyperglycemic excursions (≥ 250 mg/dl) in 15 days prior to evaluation
*p < 0.05
Total QoL and subscales
| Total (n = 312) | Male (n = 161) | CI | Female (n = 151) | CI | p value | |
|---|---|---|---|---|---|---|
| Satisfaction score (15 items) | 75 (61–86) | 77 (64–87) | 74.8–81.6 | 73 (60–85) | 72.0–78.3 | 0.180 |
| Diabetes Impact score (17 items) | 81 (74–90) | 84 (75–90) | 80.2–87.0 | 80 (72–89) | 78.6–84.9 | 0.192 |
| Social worries score (7 items) | 78 (64–92) | 82 (67–92) | 79.5–84.1 | 78 (60–93) | 76.2–82.0 | 0.226 |
| Diabetes-related worries score (4 items) | 75 (56–81) | 75 (62–87) | 72.9–79.0 | 69 (50–81) | 66.0–71.3 | 0.005* |
| Total Es-DQoL score (43 items) | 78 (68–86) | 80 (69–87) | 75.7–83.1 | 75 (65–85) | 73.6–77.5 | 0.041* |
Score range for Total Es-DQoL score and its subscales are 0–100: values are expressed by median and interquartile range; *p < 0.05. CI 95%-confidence interval
Score in psychological tests
| Variables | Total (n = 312) | Male (n = 161) | CI | Female (n = 151) | CI |
|---|---|---|---|---|---|
| Fear of hypoglycemia | 26 (20–33) | 25 (19–32) | 25.3–28.2 | 26 (21–34) | 24.4–27.6 |
| Depression (Beck) | 4 (2–11) | 4 (2–9) | 3.0–5.1 | 5 (2–13*) | 3.8–6.4 |
| State anxiety (STAI-S) | 13 (7–22) | 12 (6–18.5) | 10.3–13.7 | 15 (9–27*) | 13.5–17.5 |
| Trait anxiety (STAI-T) | 16 (10–26) | 15 (8.5–24.5) | 14.1–17.4 | 18.5 (11–27*) | 16.0–20.7 |
Values are expressed by median and interquartile range; *p < 0.05. CI 95%-confidence interval
Clinical and psychological predictive factors of QoL in multivariable regression model
| Beta coefficient | Standard error | t | p value | R2 adjusted | |
|---|---|---|---|---|---|
| Depression (Beck score) | − 0.602 | 0.121 | − 4.980 | < 0.001 | 0.642 |
| Fear of hypoglycemia (FH-15 score) | − 0.499 | 0.071 | − 7.1 | < 0.001 | |
| Glycemic instabilitya | − 0.234 | 0.082 | − 2.855 | < 0.005 | |
| Macrovascular complication (yes/no) | − 6.976 | 3.558 | − 1.961 | < 0.05 | |
| Trait anxiety (STAI-T score) | − 0.288 | 0.076 | − 3.775 | < 0.001 |
aGlycemic instability is defined as number of episodes of severe hypoglycaemia, mild hypoglycemia (≤ 70 mg/dl) and hyperglycemic excursions (≥ 250 mg/dl) in 15 days prior to evaluation
Clinical and psychological predictive factors of QoL in multivariable regression model (Male patients)
| Beta coefficient | Standard error | t | p value | R2 adjusted | |
|---|---|---|---|---|---|
| Depression (Beck score) | − 0.879 | 0.147 | − 5.979 | < 0.001 | 0.717 |
| Fear of hypoglycemia (FH-15 score) | − 0.520 | 0.085 | − 6.098 | < 0.001 | |
| Trait anxiety (STAI-T score) | − 0.275 | 0.088 | − 3.112 | < 0.005 |
Clinical and psychological predictive factors of QoL in multivariable regression model (Female patients)
| Beta coefficient | Standard error | t | p value | R2 adjusted | |
|---|---|---|---|---|---|
| Trait anxiety (STAI-T score) | − 0.415 | 0.130 | − 3.207 | < 0.005 | 0.544 |
| Fear of hypoglycemia (FH-15 score) | − 0.540 | 0.113 | − 4.797 | < 0.001 | |
| Depression (Beck score) | − 0.484 | 0.195 | − 2.483 | < 0.05 | |
| Glycemic instability* | − 0.295 | 0.136 | − 2.163 | < 0.05 |
*Glycemic instability is defined as number of episodes of severe hypoglycaemia, mild hypoglycemia (≤ 70 mg/dl) and hyperglycemic excursions (≥ 250 mg/dl) in 15 days prior to evaluation